Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD)Higher ctDNA clearance with IMNN-001 vs. controlHighly favorable safety and tolerability profile Study, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001's unique mechanism of remodeling the tumor immune microenvironment LAWRENCEVILLE, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced new positive preliminary data from its ongoin

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the June 24th & 25th Life Sciences Virtual Investor Forum are now available for on-demand viewing. REGISTER AND VIEW PRESENTATIONS HERE Select companies are accepting 1x1 management meeting requests through June 19th. Please Schedule 1x1 Meetings here. The presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Presenting Companies CompanyTicker(s)MetaVia Inc.(NASDAQ:MTVA)Nasus Pharma Ltd.(NYSE:NSRX)CytoSorbents Corporation(NASD

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoa

LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET. DATE: Thursday, June 25th, 2026TIME: 12:00 p.m. ETWebcast Registration Link HereAvailable for 1x1 meetings: Schedule 1x1 Meetings HERE This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event liv

Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million. The transaction includes 250 shares of non-redeemable, non-convertible preferred stock for $2.5 million and two secured pr

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin

LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial 800-715-9871 (U.S. and Canada/Toll Free) or 646-307-1963 (U

IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clinical data show continued median overall survival improvement with IMNN-001 Enrollment in the OVATION 3 Study, IMUNON's Phase 3 pivotal trial for IMNN-001, remains ahead of plan supported by continued strong interest from principal investigators and the medical community Company to hold conference call today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunother

The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients treated with PARP inhibitor therapy in addition to IMNN-001 and standard of care chemotherapy demonstrated median increase in OS of 24.2 months Enrollment in IMUNON's Phase 3 pivotal trial for IMNN-001 remains ahead of plan, supported by continued strong interest from investigators and medical community LAWRENCEVILLE, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced final cl

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

8-K - Imunon, Inc. (0000749647) (Filer)

S-8 - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

10-Q - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

DEF 14A - Imunon, Inc. (0000749647) (Filer)

10-K - Imunon, Inc. (0000749647) (Filer)

8-K - Imunon, Inc. (0000749647) (Filer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

3 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

4 - Imunon, Inc. (0000749647) (Issuer)

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported fin

LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, May 12, 2026 to discuss financial results for the first quarter ended March 31, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer. To participate in the call, please dial 800-715-9871 (U.S. and Canada/Toll Free) or 646-307-1963 (U

LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. EDT on Tuesday, March 31, 2026 to discuss financial results for the year ended December 31, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America/Toll Free) or 646-307-1

R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and nine-month periods ended September 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed

LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025 to discuss financial results for the third quarter ended September 30, 2025, and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711 (International/Toll) and ask for the IMUNON Third Quarter 2025 Financial Results Call. A live webcast of the

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market. "Having regained compliance with Nasdaq's minimum bid price listing requirement, investors in IMUNON's stock are assured of efficient liquidity as provided by the exchange. Our ongoing confidence in our listing with the Nasdaq coi

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, earlier today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer and the introduction of a 15% stock dividend payment to shareholders. The following is a summary of remarks by Imunon's President and

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly diagnosed advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today reported financial results for the three-month and six-month periods ended June 30, 2025, and highlighted recent business updates, including progress in advancing Phase 3 clinical development of i

LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m. ET on Tuesday, August 5, 2025 to discuss financial results for the second quarter ended June 30, 2025 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing the IMNN-001 development program in a Phase 3 clinical trial in advanced ovarian cancer. To participate in the call, interested parties may dial 833-816-1132 (Toll-Free/North America) or 412-317-0711

Stock Dividend Reflects Company's Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that its Board of Directors approved a 15% stock dividend, 0.15 shares of common stock per share of common stock and per each common stock equivalent with dividend rights. This stock grant reflects IMUNON's confidence in its clinical programs, long-term growth strategy, and its dedication to rewarding shareholders. The stock dividend program will distribute a total of approximately 448

Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the appointment of Douglas V. Faller, M.D., Ph.D., as chief medical officer, effective February 18, 2025. In this role, Dr. Faller will lead the company's clinical strategy including advancing its lead program IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, which is on track to enter a Phase 3 pivotal trial in the first quarter of 202

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021. Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Stud

Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Sebastien Hazard, M.D. as Chief Medical Officer, effective December 11, 2023. Dr. Hazard brings to IMUNON a strong background in building and leading clinical development organizations, most recently at Bicycle Therapeutics. He will report to IMUNON's President and Chief Executive Officer, Dr. Corinne Le

Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology. LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company's scientific advisory board. Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. He joins current scientific advisory board members Dan H. Bar

SC 13G - Imunon, Inc. (0000749647) (Subject)

SC 13G/A - Imunon, Inc. (0000749647) (Subject)

SC 13G - Imunon, Inc. (0000749647) (Subject)